Paloma Partners’s Enanta Pharmaceuticals ENTA Stock Holding History

Paloma Partners’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-3,301	Closed	-$234K	–	1747
2018 Q4	$234K	Buy	+3,301	New	+$253K	0.01%	977
2018 Q2	–	Sell	-15,001	Closed	-$1.21M	–	1771
2018 Q1	$1.21M	Buy	+15,001	New	+$1.15M	0.02%	876
2017 Q1	–	Sell	-22,700	Closed	-$760K	–	2023
2016 Q4	$760K	Buy	+22,700	New	+$651K	0.01%	1312

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Paloma Partners's ENTA Position: Q1 2019 in Review

Paloma Partners sold out of Enanta Pharmaceuticals (ENTA) in Q1 2019, closing a stake of 3,301 shares — an estimated $234K sold.

Paloma Partners first reported a position in ENTA in Q4 2016 and held it in 3 quarters. The position peaked at $1.21M in Q1 2018. 195 funds tracked by Wall St. Rank hold ENTA as of Q1 2019.

Paloma Partners reported no remaining Enanta Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Paloma Partners sold 3,301 Enanta Pharmaceuticals shares in Q1 2019, an estimated $234K.
Paloma Partners first reported a position in Enanta Pharmaceuticals in Q4 2016 and held it in 3 quarters.
Paloma Partners's Enanta Pharmaceuticals position peaked at $1.21M in Q1 2018.
195 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2019.

Based on Paloma Partners's 13F filing for Q1 2019, filed 15 May 2019.